French healthtech startup ArcaScience secured $7 million in seed funding. The Moon Venture led this round; consequently, ArcaScience will expand its AI benefit-risk platform for drug development into the U.S. and U.K.
Founded in 2018, ArcaScience develops an AI platform that transforms vast biomedical data into actionable benefit-risk insights, significantly impacting AI drug development. It integrates over 100 billion data points, furthermore employing specialized AI models.
Accelerating Drug Development with AI
ArcaScience addresses the challenge of underutilized biomedical data in drug development. Up to 90% of valuable data often remains unused. The platform federates disparate sources, consequently extracting key indicators like adverse events and biomarkers.
Major pharmaceutical companies, including Sanofi and AstraZeneca, currently adopt ArcaScience's solution. This optimizes clinical operations and pharmacovigilance.
The new capital will also fund a patient-facing solution for pediatric brain cancer and dermatological diseases. Moreover, ArcaScience plans to hire a chief medical officer, strengthening its healthtech leadership. Other firms like BenevolentAI and Recursion Pharmaceuticals also leverage AI in this space.
